Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimportation Law Unlikely This Year Despite Democratic Pressure

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Majority Leader Frist says he does not expect to fit Rx import language into the schedule during the session’s remaining days. The Senate Health Committee has no plans to markup a bill.

You may also be interested in...



Reimportation Is "Phony" Issue, Waxman Says, But Driven By Real Pricing Problems

Reimportation is not the solution to high U.S. drug prices, Rep. Henry Waxman (D-Calif.) said

Reimportation Is "Phony" Issue, Waxman Says, But Driven By Real Pricing Problems

Reimportation is not the solution to high U.S. drug prices, Rep. Henry Waxman (D-Calif.) said

Reimportation Advocates Have Support Of "Rogue" Pfizer Exec

Parallel trade of pharmaceuticals in Europe demonstrates that U.S. could safely implement an importation program, Pfizer VP-Marketing Peter Rost says at Capitol Hill press conference. Rost is a former Pharmacia exec who describes his advocacy as a "private citizen" sharing "personal experience."

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel